GET DAILY SIGNALSWhy Is Inogen (INGN) Stock Down -16.54% Today?
Key Takeaways
- Shares of Inogen (INGN) tumbled roughly 16.5% in Thursday's session, sliding from a prior close of $6.77 to about $5.65.
- The selloff followed third-quarter 2026 results that missed revenue expectations, alongside sharply reduced full-year guidance.
- A widening GAAP loss — including a $10.6 million goodwill impairment — compounded investor concerns.
- Weakness in the company's international business, driven by softer European capital spending, offset a return to U.S. growth.
- A leadership transition and new $20 million cost-reduction program were announced but failed to reassure traders.
- Traders are now watching whether the stock stabilizes above recent support and how the cost-cutting plan progresses.
- For more context on valuation and expectations, explore Price Targets, Earnings, and Forecast pages for INGN.
- Discover how AI-driven strategies are positioning across thousands of stocks in the Trending AI Robots section.
Opening Summary
Inogen, Inc. (INGN), a medical technology company that develops and markets portable oxygen concentrators for patients with chronic respiratory conditions, saw its shares plunge approximately 16.5% on Thursday. The stock fell to roughly $5.65, down from a previous session close of $6.77, as investors reacted to a third-quarter earnings report that missed revenue estimates and included a steep cut to the company's financial outlook. The market reaction reflected a decisive bearish repricing after results revealed softer international demand, a wider reported loss, and guidance that landed well below analyst expectations.
Earnings Results and Guidance
The primary catalyst behind the decline was Inogen's third-quarter 2026 report, released after the prior session's close. Revenue from continuing operations came in at $77.2 million, down 2.4% year over year and well short of consensus estimates near $94 million. Reported loss per share from continuing operations widened to $0.56, a figure inflated by a non-cash goodwill impairment of $10.6 million tied to the company's market capitalization falling below book equity.
Guidance compounded the disappointment. Management set fourth-quarter revenue guidance of $65 million to $68 million and full-year revenue of $298 million to $301 million from continuing operations — figures that sit materially below analyst forecasts. The company also replaced its prior adjusted EBITDA target with an expectation of a full-year adjusted net loss of $7 million to $8 million, signaling that profitability remains further out than investors had hoped. The combination of a top-line miss and a reset outlook drove the earnings-driven selloff.
International Weakness and Margin Compression
A geographic divergence in the quarter underscored the growth concerns. U.S. sales rose 3.8% to $42.2 million, marking the first year-over-year increase since late 2024 and benefiting from new product contributions. However, international sales fell 9% to $34.9 million, snapping a prolonged streak of double-digit growth, as softer capital spending and inventory management among large European customers weighed on demand. Management expects that international softness to persist into the fourth quarter.
The revenue mix also pressured profitability, with adjusted gross margin slipping to 44.2% from 45.9% a year earlier. Lower-margin international sales more than offset manufacturing cost improvements, reinforcing investor unease about near-term earnings power.
Leadership Transition and Strategic Reset
The quarter coincided with a leadership change and restructuring announcements. The board appointed Andy Reding, previously chief operating officer, as president and chief executive officer. On his first earnings call, Reding acknowledged that results "are not where they need to be," and the company did not take live analyst questions — a detail that added to investor caution.
Management also announced a $20 million annualized cost-reduction program, with the first $10 million expected by the end of 2026, and confirmed completion of the divestiture of its U.S. oxygen rental business for up to $24.8 million. While these self-help measures simplify the business and target more than $40 million in combined annualized savings, they did not offset the weaker near-term revenue trajectory in traders' eyes.
Market Context and Trading Activity
The move was accompanied by elevated trading activity as investors repriced the stock following the results. The decline marked a sharp reversal from a recent rally that had lifted shares over the prior month, effectively erasing much of those gains in a single session. The stock's slide reflects company-specific catalysts rather than a broad market move, as the selloff stemmed directly from the earnings miss and guidance reset rather than sector-wide or macro-driven momentum in healthcare equipment names.
From a technical standpoint, the drop pushed shares back toward the lower end of their recent trading range, testing levels last seen earlier in the year and raising questions about whether buyers will step in to defend those areas.
What Comes Next for INGN
Looking ahead, investors will focus on whether the company can execute on its cost-reduction program and whether U.S. growth can accelerate while international demand stabilizes. The fourth-quarter guidance implies continued pressure, and the company's shift away from an EBITDA target toward an adjusted net loss reduces the clarity of its profitability roadmap. Risks include persistent European softness, potential channel mix shifts, and execution uncertainty under new leadership.
On the positive side, Inogen maintains a debt-free balance sheet with a strong cash position, and the rental divestiture plus cost cuts could improve its cost structure over time. Traders will monitor upcoming quarterly results and any commentary on the commercial strategy as the new management team refines its priorities.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that have demonstrated strong performance under current market conditions. While Tickeron offers hundreds of AI trading bots covering thousands of tickers, only the strongest performers are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches to explore. Visit the page to see which AI strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INGN in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 06, 2026
INGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 40 cases where INGN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
INGN moved above its 50-day moving average on October 01, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for INGN crossed bullishly above the 50-day moving average on October 08, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 61%.
Following a +5.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where INGN advanced for three days, in 190 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
The Aroon Indicator entered an Uptrend today. In 113 of 169 cases where INGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
Bearish Trend Analysis
The 10-day RSI Indicator for INGN moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 28 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 58 cases where INGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INGN as a result. In 70 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for INGN turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 38 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 39 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. INGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.915) is normal, around the industry mean (4.137). P/E Ratio (-6.626) is within average values for comparable stocks, (2.620). Projected Growth (PEG Ratio) (1.290) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.393) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a medical technology company
Industry MedicalNursingServices
Advertisement